Oregon Public Employees Retirement Fund maintained its position in Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 77,986 shares of the medical research company’s stock at the end of the second quarter. Oregon Public Employees Retirement Fund’s holdings in Amgen were worth $13,432,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Ally Financial Inc. purchased a new position in Amgen during the fourth quarter valued at $2,632,000. Nations Financial Group Inc. IA ADV purchased a new position in Amgen during the fourth quarter valued at $252,000. Marietta Wealth Management LLC bought a new position in shares of Amgen during the fourth quarter valued at about $1,379,000. Flinton Capital Management LLC bought a new position in shares of Amgen during the fourth quarter valued at about $6,398,000. Finally, Cpcm LLC bought a new position in shares of Amgen during the fourth quarter valued at about $1,266,000. Institutional investors and hedge funds own 79.53% of the company’s stock.
Amgen Inc. (NASDAQ:AMGN) traded up 0.19% during trading on Friday, reaching $169.43. The company had a trading volume of 1,571,584 shares. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $184.21. The firm has a market capitalization of $123.63 billion, a price-to-earnings ratio of 15.43 and a beta of 1.35. The stock has a 50 day moving average price of $174.48 and a 200 day moving average price of $167.49.
Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.84 EPS. On average, equities research analysts predict that Amgen Inc. will post $12.57 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Thursday, August 17th will be issued a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a yield of 2.71%. The ex-dividend date of this dividend is Tuesday, August 15th. Amgen’s dividend payout ratio (DPR) is presently 41.93%.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by BNB Daily and is the sole property of of BNB Daily. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.baseball-news-blog.com/2017/08/13/amgen-inc-amgn-stake-held-by-oregon-public-employees-retirement-fund-updated-updated-updated.html.
Several equities analysts have recently issued reports on the company. BMO Capital Markets cut Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 price objective for the company. in a research note on Friday, July 21st. They noted that the move was a valuation call. Jefferies Group LLC restated a “hold” rating and set a $180.00 target price on shares of Amgen in a research note on Monday, May 22nd. Leerink Swann restated a “market perform” rating and set a $161.00 target price on shares of Amgen in a research note on Thursday, June 22nd. Credit Suisse Group set a $177.00 target price on Amgen and gave the stock a “hold” rating in a research note on Friday, July 14th. Finally, Cowen and Company reiterated an “outperform” rating and issued a $209.00 price objective on shares of Amgen in a research note on Wednesday, April 19th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company’s stock. Amgen has an average rating of “Buy” and an average price target of $186.64.
In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the transaction, the senior vice president now owns 24,214 shares in the company, valued at approximately $3,738,641.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.20% of the stock is currently owned by corporate insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.